Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia.

Balla A, Schneider S, Sershen H, Javitt DC.

Eur Neuropsychopharmacol. 2012 Dec;22(12):902-10. doi: 10.1016/j.euroneuro.2012.03.006. Epub 2012 May 5.

2.

Modulation of striatal dopamine release by glycine transport inhibitors.

Javitt DC, Hashim A, Sershen H.

Neuropsychopharmacology. 2005 Apr;30(4):649-56.

3.
4.

Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.

Balla A, Koneru R, Smiley J, Sershen H, Javitt DC.

Neuropsychopharmacology. 2001 Aug;25(2):157-64.

5.

Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists.

Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H.

Neuropsychopharmacology. 2004 Feb;29(2):300-7.

6.

GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum.

Balla A, Nattini ME, Sershen H, Lajtha A, Dunlop DS, Javitt DC.

Neuropharmacology. 2009 Apr;56(5):915-21. doi: 10.1016/j.neuropharm.2009.01.021. Epub 2009 Feb 6.

7.

Inhibition of striatal dopamine release by glycine and glycyldodecylamide.

Javitt DC, Sershen H, Hashim A, Lajtha A.

Brain Res Bull. 2000 Jun;52(3):213-6.

PMID:
10822163
8.

Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release.

Balla A, Sershen H, Serra M, Koneru R, Javitt DC.

Neuropsychopharmacology. 2003 Jan;28(1):34-44.

9.

Development of dopamine and N-methyl-D-aspartate systems in rat brain: the effect of prenatal phencyclidine exposure.

Ali SF, Holson RR, Newport GD, Slikker W Jr, Bowyer JF.

Brain Res Dev Brain Res. 1993 May 21;73(1):25-33.

PMID:
7685665
10.

Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.

Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J, Chaki S, Hikichi H.

Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.

PMID:
25300471
11.
12.

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

Javitt DC, Balla A, Sershen H, Lajtha A.

Biol Psychiatry. 1999 Mar 15;45(6):668-79.

PMID:
10187996
13.

Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo.

Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL.

Life Sci. 1989;45(12):1065-72.

PMID:
2796597
14.

Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.

Sershen H, Hashim A, Dunlop DS, Suckow RF, Cooper TB, Javitt DC.

Neurochem Res. 2016 Feb;41(1-2):398-408. doi: 10.1007/s11064-016-1838-8. Epub 2016 Feb 8.

15.

Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis.

Nishijima K, Kashiwa A, Hashimoto A, Iwama H, Umino A, Nishikawa T.

Synapse. 1996 Apr;22(4):304-12.

PMID:
8867025
16.

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine.

Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M.

Eur Neuropsychopharmacol. 2008 Jun;18(6):414-21. Epub 2007 Sep 4.

PMID:
17804206
17.

Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.

Chaki S, Shimazaki T, Karasawa J, Aoki T, Kaku A, Iijima M, Kambe D, Yamamoto S, Kawakita Y, Shibata T, Abe K, Okubo T, Sekiguchi Y, Okuyama S.

Psychopharmacology (Berl). 2015 Aug;232(15):2849-61. doi: 10.1007/s00213-015-3920-3. Epub 2015 Apr 15.

PMID:
25869273
18.

Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum.

Balla A, Hashim A, Burch S, Javitt DC, Lajtha A, Sershen H.

Neurochem Res. 2001 Sep;26(8-9):1001-6.

PMID:
11699927
19.

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.

Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2005 Nov;30(11):1963-85.

20.

Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Nagy K, Marko B, Zsilla G, Matyus P, Pallagi K, Szabo G, Juranyi Z, Barkoczy J, Levay G, Harsing LG Jr.

Neurochem Res. 2010 Dec;35(12):2096-106. doi: 10.1007/s11064-010-0241-0. Epub 2010 Aug 20.

PMID:
20725779

Supplemental Content

Support Center